Current Hepatitis Reports

, Volume 11, Issue 2, pp 95–101

Update on the Management of HBV-HDV Coinfection

  • Heiner Wedemeyer
  • Svenja Hardtke
  • Michael P. Manns
Hepatitis B: Therapeutics (P Martin, Section Editor)
  • 102 Downloads

Abstract

Hepatitis Delta is caused by coinfection with the hepatitis B virus and the hepatitis D virus and has to be considered as the most severe form of viral hepatitis. HDV infection may affect between 15 and 20 Million individuals worldwide with significant regional differences of HDV prevalence rates. The diagnosis of hepatitis delta in HBsAg-positive individuals is based on the detection of HDV antibodies and HDV RNA. Interferon alpha remains the only effective treatment as currently available nucleoside or nucleotide analogous are not effective against HDV. Recent trials showed that about 25 % of HDV-infected patients may clear HDV RNA by therapy with pegylated interferon alpha. Liver transplantation remains the only treatment option for the majority patients with advanced liver disease

Keywords

HDV Treatment Liver disease Epidemiology 

References

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. 1.
    Hadziyannis SJ. Review: hepatitis delta. J Gastroenterol Hepatol. 1997 Apr;12(4):289–98.PubMedCrossRefGoogle Scholar
  2. 2.
    Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nature Reviews Gastroenterology & Hepatology. 2010 Jan;7(1):31–40.CrossRefGoogle Scholar
  3. 3.
    Niro GA, Casey JL, Gravinese E, Garrubba M, et al. Intrafamilial transmission of hepatitis delta virus: molecular evidence. Journal of Hepatology. 1999 Apr;30(4):564–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011 Jul 2;378(9785):73–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Radjef N, Gordien E, Ivaniushina V, Anais P, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus suggesting a deltavirus genus to be composed of at least seven major clades. Journal of Hepatology. 2004 Apr;40:110-.Google Scholar
  6. 6.
    Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection - Not a vanishing disease in Europe! Hepatology. 2007 May;45(5):1331–2.PubMedCrossRefGoogle Scholar
  7. 7.
    Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, et al. Chronic hepatitis D: A vanishing disease? An Italian multicenter study. Hepatology. 2000 Oct;32(4):824–7.PubMedCrossRefGoogle Scholar
  8. 8.
    • Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, et al. Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users. J Infect Dis. 2010;202(6):845–52. Surprisingly high prevalence of HDV infection among IV drug addicts followed in Baltimore.PubMedCrossRefGoogle Scholar
  9. 9.
    Farci P. Delta hepatitis: an update. Journal of Hepatology. 2003;39:S212-S9.PubMedCrossRefGoogle Scholar
  10. 10.
    Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver International. 2008 Apr;28(4):494–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. Journal of Medical Virology. 2005 Dec;77(4):491–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Erhardt A, Knuth R, Sagir A, Kirschberg O, Heintges T, Haussinger D. Socioepidemiological data on hepatitis delta in a German University Clinic - Increase in patients from Eastern Europe and the Former Soviet Union. Zeitschrift Fur Gastroenterologie. 2003 Jun;41(6):523–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009 Dec;16(12):883–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Cross TJS, Dancer R, Horner M, Harrison PM, Agarwal K. The impact of CO-INFECTION of hepatitis delta and human immunodeficiency virus on the natural history of chronic hepatitis B. Gut. 2008 Jan;57:A75-A.Google Scholar
  15. 15.
    Mele A, Mariano A, Tosti ME, Stroffolini T, et al. Acute delta hepatitis in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. (vol 44, e17, 2007). Clinical Infectious Diseases. 2007 Apr 1;44(7):1016-.Google Scholar
  16. 16.
    Le Gal F, Castelneau C, Gault E, Al Hawajri N, Marcellin P, Deny P. Hepatitis D virus infection - Not a vanishing disease in Europe! Reply. Hepatology. 2007 May;45(5):1332–3.CrossRefGoogle Scholar
  17. 17.
    Soriano V, Grint D, Monforte AD, Horban A, et al. Hepatitis delta in HIV-infected individuals in Europe. Aids. 2011 Oct 23;25(16):1987–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor JM. Hepatitis delta virus. Virology. 2006 Jan 5;344(1):71–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Su CW, Huang YH, Huo TI, Shih HH, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Journal of Hepatology. 2006;44:S178-S.CrossRefGoogle Scholar
  20. 20.
    Alvarado-Mora MV, Romano CM, Gomes-Gouvea MS, Gutierrez MF, Carrilho FJ, Pinho JR. Dynamics of hepatitis D (delta) virus genotype 3 in the Amazon region of South America. Infect Genet Evol. 2011 Aug;11(6):1462–8.PubMedCrossRefGoogle Scholar
  21. 21.
    •• Fattovich G, Giustina G, Christensen E, Pantalena M, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000;46(3):420–6. European multicenter study demonstrating the effects of hepatitis delta on morbidity and mortality.PubMedCrossRefGoogle Scholar
  22. 22.
    Fattovich G, Boscaro S, Noventa F, Pornaro E, et al. Influence of Hepatitis-Delta-Virus Infection on Progression to Cirrhosis in Chronic Hepatitis Type-B. Journal of Infectious Diseases. 1987 May;155(5):931–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Rizzetto M. Hepatitis D: Thirty years after. Journal of Hepatology. 2009 May;50(5):1043–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Uzunalimoglu O, Yurdaydin C, Cetinkaya H, Bozkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Digestive Diseases and Sciences. 2001 May;46(5):1022–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Yurdaydin C. Delta hepatitis in Turkey: decreasing but not vanishing and still of concern. Turk J Gastroenterol. 2006 Mar;17(1):74–5.PubMedGoogle Scholar
  26. 26.
    Niro GA, Smedile A, Ippolito AM, Ciancio A, et al. Outcome of chronic delta hepatitis in Italy: A long-term cohort study. Journal of Hepatology. 2010 Nov;53(5):834–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Romeo R, Del Ninno E, Rumi M, Russo A, et al. A 28-Year Study of the Course of Hepatitis Delta Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. Gastroenterology. 2009 May;136(5):1629–38.PubMedCrossRefGoogle Scholar
  28. 28.
    Castellares C, Barreiro P, Martin-Carbonero L, Labarga P, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008 Mar;15(3):165–72.PubMedGoogle Scholar
  29. 29.
    Sheng WH, Hung CC, Kao JH, Chang SY, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: A matched cohort study. Clinical Infectious Diseases. 2007 Apr 1;44(7):988–95.PubMedCrossRefGoogle Scholar
  30. 30.
    Calle-Serrano bH, B;Homs,M;Erhardt,A;Deterding,K;Jaroszewicz,J;Cornberg,M;Manns,M.P.;Buti,M;Wedemeyer,H Development and Evaluation of a Baseline Event-Anticipation (BEA)-Score for Hepatitis Delta. AASLD; 2011; San Francisco; 2011. p. ID 171.Google Scholar
  31. 31.
    Aslan N, Yurdaydin C, Bozkaya H, Baglan P, et al. Analysis and function of delta-hepatitis virus-specific cellular immune responses. Journal of Hepatology. 2003 Apr;38:15–6.CrossRefGoogle Scholar
  32. 32.
    Nisini R, Paroli M, Accapezzato D, Bonino F, et al. Human CD4(+) T-cell response to hepatitis delta virus: Identification of multiple epitopes and characterization of T-helper cytokine profiles. Journal of Virology. 1997 Mar;71(3):2241–51.PubMedGoogle Scholar
  33. 33.
    Huang YH, Tao MH, Hu CP, Syu WJ, Wu JC. Identification of novel HLA-A•0201-restricted CD8(+) T-cell epitopes on hepatitis delta virus. Journal of General Virology. 2004 Oct;85:3089–98.PubMedCrossRefGoogle Scholar
  34. 34.
    Grabowski J, Yurdaydin C, Zachou K, Buggisch P, et al. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver International. 2011 Oct;31(9):1395–405.PubMedCrossRefGoogle Scholar
  35. 35.
    Aslan N, Yurdaydin C, Wiegand J, Greten T, et al. Cytotoxic CD4(+) T cells in viral hepatitis. Journal of Viral Hepatitis. 2006 Aug;13(8):505–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Zachou K, Yurdaydin C, Drebber U, Dalekos GN, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver International. 2010 Mar;30(3):430–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Negro F, Bergmann KF, Baroudy BM, Satterfield W, Purcell RH, Gerin JL. Chronic Hepatitis Delta Virus (Hdv) Infection in the Chimpanzee Animal-Model. Gastroenterology. 1988 May;94(5):A576-A.Google Scholar
  38. 38.
    Raimondo G, Brunetto MR, Pontisso P, Smedile A, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus hepatitis C virus-coinfected patients. Hepatology. 2006 Jan;43(1):100–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Jardi R, Rodriguez F, Buti M, Costa X, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001 Aug;34(2):404–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Sagnelli E, Coppola N, Scolastico C, Filippini P, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000 Nov;32(5):1106–10.PubMedCrossRefGoogle Scholar
  41. 41.
    Lutgehetmann M, Petersen J, Volz T, Allweiss L, et al. The Entry Inhibitor Myrcludex-B Efficiently Blocks Viral Spreading in Vivo in Human Liver Chimeric Upa/Scid Mice Previously Infected with Hepatitis B Virus. Hepatology. 2011 Oct;54:372a-a.Google Scholar
  42. 42.
    Williams V, Brichler S, Radjef N, Lebon P, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. Journal of General Virology. 2009 Nov;90:2759–67.PubMedCrossRefGoogle Scholar
  43. 43.
    Wedemeyer H. Re-emerging interest in hepatitis delta: New insights into the dynamic interplay between HBV and HDV. Journal of Hepatology. 2010 May;52(5):627–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. Journal of Hepatology. 2010 May;52(5):658–64.PubMedCrossRefGoogle Scholar
  45. 45.
    Deterding K, Pothakamuri SV, Schlaphoff V, Hadem J, et al. Clearance of Chronic HCV Infection During Acute Delta Hepatitis. Infection. 2009 Apr;37(2):159–62.PubMedCrossRefGoogle Scholar
  46. 46.
    Mederacke I CY, A. Großhennig, A. Erhardt, Y. Cakaloglu,K. Yalcin,S. Gurel,S. Zeuzem,K. Zachou,C. Chatzikyrkou,H. Bozkaya,G. N. Dalekos,M. P. Manns and H. Wedemeyer; on behalf of Hep-Net/International Delta Hepatitis Study Group Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. Journal of Viral Hepatitis. 2012;in press.Google Scholar
  47. 47.
    Mederacke I, Bremer B, Heidrich B, Kirschner J, et al. Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics. Journal of Clinical Microbiology. 2010 Jun;48(6):2022–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Niro GA, Gioffreda D, Fontana R. Hepatitis delta virus infection: Open issues. Digestive and Liver Disease. 2011 Jan;43:S19-S24.PubMedCrossRefGoogle Scholar
  49. 49.
    Erhardt A, Gerlich W, Starke C, Wend U, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha 2b. Liver International. 2006 Sep;26(7):805–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Janssen HLA, Lau GKK. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs. Hepatology. 2005 Dec;42(6):1459-.PubMedCrossRefGoogle Scholar
  51. 51.
    Wedemeyer H, Boker KHW, Pethig K, Petzold DR, et al. Famciclovir treatment of chronic hepatitis B in heart transplant recipients: A prospective trial. Transplantation. 1999 Nov 27;68(10):1503–11.PubMedCrossRefGoogle Scholar
  52. 52.
    Yurdaydin C, Bozkaya H, Gurel S, Tillmann HL, et al. Famciclovir treatment of chronic delta hepatitis. Journal of Hepatology. 2002 Aug;37(2):266–71.PubMedCrossRefGoogle Scholar
  53. 53.
    Wolters LMM, van Nunen AB, Honkoop P, Vossen ACTM, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. Journal of Viral Hepatitis. 2000 Nov;7(6):428–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Niro GA, Ciancio A, Tillman HL, Lagget M, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Alimentary Pharmacology & Therapeutics. 2005 Aug 1;22(3):227–32.PubMedCrossRefGoogle Scholar
  55. 55.
    Yurdaydin C, Bozkaya H, Onder FO, Senturk H, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine plus interferon vs interferon. Journal of Viral Hepatitis. 2008 Apr;15(4):314–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Lau DTY, Doo E, Park Y, Kleiner DE, et al. Lamivudine for chronic delta hepatitis. Hepatology. 1999 Aug;30(2):546–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Sheldon J, Ramos B, Toro C, Rios P, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antiviral Therapy. 2008;13(1):97–102.PubMedGoogle Scholar
  58. 58.
    Casey J, Cote PJ, Toshkov IA, Chu CK, et al. Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks. Antimicrobial Agents and Chemotherapy. 2005 Oct;49(10):4396–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Yakut M, Seven G, Baran B, Kabacam G, et al. Clevudine Treatment of Chronic Delta Hepatitis. Hepatology. 2010 Oct;52(4):554a-a.Google Scholar
  60. 60.
    Niro GA, Ciancio A, Gaeta GB, Marrone A, et al. Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta. Journal of Clinical Virology. 2006 Jul;36:S161-S.CrossRefGoogle Scholar
  61. 61.
    Gunsar F, Akarca US, Ersoz G, Kobak AC, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antiviral Therapy. 2005;10(6):721–6.PubMedGoogle Scholar
  62. 62.
    Garripoli A, Dimarco V, Cozzolongo R, Costa C, et al. Ribavirin Treatment for Chronic Hepatitis-D - a Pilot-Study. Liver. 1994 Jun;14(3):154–7.PubMedGoogle Scholar
  63. 63.
    •• Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–31. Largest randomized trial to investigate the efficacy of pegylated inferferon in hepatitis delta.PubMedCrossRefGoogle Scholar
  64. 64.
    Bordier BB, Ohkanda J, Liu P, Lee SY, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. Journal of Clinical Investigation. 2003 Aug;112(3):407–14.PubMedGoogle Scholar
  65. 65.
    Petersen J, Dandri M, Mier W, Lutgehetmann M, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology. 2008 Mar;26(3):335–41.PubMedCrossRefGoogle Scholar
  66. 66.
    Samuel D, Muller R, Alexander G, Fassati L, et al. Liver-Transplantation in European Patients with the Hepatitis-B Surface-Antigen. New England Journal of Medicine. 1993 Dec 16;329(25):1842–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Rosenau J, Kreutz T, Kujawa M, Bahr MJ, et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. Journal of Hepatology. 2007 Apr;46(4):635–44.PubMedCrossRefGoogle Scholar
  68. 68.
    Mederacke I, Filmann N, Yurdaydin C, Bremer B, et al. Prolonged Intrahepatic Hepatitis Delta Antigen Persistence after Liver Transplantation (Ltx) Despite Rapid Early Serum Hdv Rna Decline after Ltx. Journal of Hepatology. 2011 Mar;54:S153-S.CrossRefGoogle Scholar
  69. 69.
    Smedile A, Casey JL, Cote PJ, Durazzo M, et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology. 1998 Jun;27(6):1723–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Heiner Wedemeyer
    • 1
  • Svenja Hardtke
    • 1
  • Michael P. Manns
    • 1
  1. 1.Department of Gastroenterology, Hepatology and EndocrinologyHannover Medical SchoolHannoverGermany

Personalised recommendations